Skip to content

Study · Case report or series · n = 1 · 2025

11 results

Suspected liraglutide (glucagon-like peptide-1 receptor agonist)-induced hyperthyroidism: A case report.

Md Sabudin SNS, Yaacob LH, Che Omar MR

Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia7 Aug 2025

PMID40949169 (opens in a new tab)PMCIDPMC12432342 (opens in a new tab)DOI10.51866/cr.886 (opens in a new tab)PepBankPUB-40949169
Download PDFPubMedAsk about this study
Jump to 11 results

Summary

Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is widely used for weight management and glycaemic control. While generally well-tolerated, various adverse effects have been reported. Thyroid dysfunction, particularly hyperthyroidism, is rare. This report describes the case of a 34-year-old woman with new-onset hyperthyroidism following liraglutide use for weight loss. The patient presented with worsening palpitations and insomnia after 3 weeks of liraglutide use. She had no prior thyroid disease or significant family history. Examination revealed sinus tachycardia with no goitre or tremors. Laboratory findings confirmed hyperthyroidism with a suppressed TSH level (0.03 mlU/L) and an elevated free T4 level (20.8 pmol/L). Thyrotropin receptor antibody was negative, ruling out Graves' disease. Liraglutide was discontinued, and the patient was treated with carbimazole and propranolol, resulting in symptom resolution and normalisation of thyroid function within weeks. Liraglutide-induced thyroid dysfunction is poorly understood. Possible mechanisms include GLP-1 receptor activity in thyroid tissue, disruption of the hypothalamic-pituitary-thyroid axis or inflammation of thyroid follicular cells. This case demonstrates a strong temporal association between liraglutide use and hyperthyroidism, which resolved upon drug discontinuation. Although thyroid dysfunction with GLP-1 RAs has been noted in preclinical studies, human data remain limited. This case highlights a rare adverse effect of liraglutide and underscores the need for vigilance when monitoring patients on GLP-1 RAs. Monitoring of thyroid function should be considered in symptomatic patients. Further research is warranted to better understand the underlying mechanisms and prevalence of GLP-1 RA-induced thyroid abnormalities.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study11

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 34-year-old woman, new-onset hyperthyroidism occurred following liraglutide use for weight loss.

    In plain wordsIn one woman, hyperthyroidism occurred after liraglutide use.

    Peptide
    Liraglutide
    Outcome
    Not applicableHyperthyroidism
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    This report describes the case of a 34-year-old woman with new-onset hyperthyroidism following liraglutide use for weight loss.
    2 context sentences
    Summary · context
    The patient presented with worsening palpitations and insomnia after 3 weeks of liraglutide use.
    Summary · context
    She had no prior thyroid disease or significant family history.
  2. 02HumanCase report or seriesSafety outcome

    In a 34-year-old woman, worsening palpitations occurred after 3 weeks of liraglutide use.

    In plain wordsIn one woman, palpitations worsened after 3 weeks of liraglutide use.

    Peptide
    Liraglutide
    Outcome
    IncreasePalpitations
    Study

    n = 1

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    The patient presented with worsening palpitations and insomnia after 3 weeks of liraglutide use.
    2 context sentences
    Summary · context
    This report describes the case of a 34-year-old woman with new-onset hyperthyroidism following liraglutide use for weight loss.
    Summary · context
    She had no prior thyroid disease or significant family history.
  3. 03HumanCase report or seriesSafety outcome

    In a 34-year-old woman using liraglutide for weight loss, insomnia worsened after 3 weeks; no isolated causal contrast was established.

    In plain wordsIn one woman using liraglutide for weight loss, insomnia worsened after 3 weeks; an isolated drug cause was unproven.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsomnia
    Study

    n = 1

    Outcome group
    Adverse events · Sleep
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    The patient presented with worsening palpitations and insomnia after 3 weeks of liraglutide use.
    2 context sentences
    Summary · context
    This report describes the case of a 34-year-old woman with new-onset hyperthyroidism following liraglutide use for weight loss.
    Summary · context
    She had no prior thyroid disease or significant family history.
  4. 04HumanCase report or seriesSafety outcome

    In a 34-year-old woman after liraglutide use, TSH was suppressed at 0.03 mlU/L.

    In plain wordsIn one woman after liraglutide use, TSH was low.

    Peptide
    Liraglutide
    Outcome
    DecreaseTSH level
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Measurements

    TSH
    0.03 mlU/L
    after liraglutide use

    Source sentences

    Summary
    Laboratory findings confirmed hyperthyroidism with a suppressed TSH level (0.03 mlU/L) and an elevated free T4 level (20.8 pmol/L).
    3 context sentences
    Summary · context
    This report describes the case of a 34-year-old woman with new-onset hyperthyroidism following liraglutide use for weight loss.
    Summary · context
    The patient presented with worsening palpitations and insomnia after 3 weeks of liraglutide use.
    Summary · context
    She had no prior thyroid disease or significant family history.
  5. 05HumanCase report or seriesSafety outcome

    In a 34-year-old woman after liraglutide use, free T4 was elevated at 20.8 pmol/L.

    In plain wordsIn one woman after liraglutide use, free T4 was high.

    Peptide
    Liraglutide
    Outcome
    IncreaseFree T4 level
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Measurements

    free T4
    20.8 pmol/L
    after liraglutide use

    Source sentences

    Summary
    Laboratory findings confirmed hyperthyroidism with a suppressed TSH level (0.03 mlU/L) and an elevated free T4 level (20.8 pmol/L).
    3 context sentences
    Summary · context
    This report describes the case of a 34-year-old woman with new-onset hyperthyroidism following liraglutide use for weight loss.
    Summary · context
    The patient presented with worsening palpitations and insomnia after 3 weeks of liraglutide use.
    Summary · context
    She had no prior thyroid disease or significant family history.
  6. 06HumanCase report or seriesSafety outcome

    In a 34-year-old woman after 3 weeks of liraglutide use, examination revealed sinus tachycardia.

    In plain wordsIn one woman after 3 weeks of liraglutide use, examination found sinus tachycardia.

    Peptide
    Liraglutide
    Outcome
    Not applicableSinus tachycardia
    Study

    n = 1

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Examination revealed sinus tachycardia with no goitre or tremors.
    3 context sentences
    Summary · context
    This report describes the case of a 34-year-old woman with new-onset hyperthyroidism following liraglutide use for weight loss.
    Summary · context
    The patient presented with worsening palpitations and insomnia after 3 weeks of liraglutide use.
    Summary · context
    She had no prior thyroid disease or significant family history.
  7. 07HumanCase report or seriesSafety outcome

    In a 34-year-old woman after 3 weeks of liraglutide use for weight loss, examination found no goitre; this was a descriptive case observation.

    In plain wordsIn one woman after liraglutide use, examination found no goitre; this was a case observation.

    Peptide
    Liraglutide
    Outcome
    Not applicableNo goitre on examination
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Examination revealed sinus tachycardia with no goitre or tremors.
    2 context sentences
    Summary · context
    This report describes the case of a 34-year-old woman with new-onset hyperthyroidism following liraglutide use for weight loss.
    Summary · context
    The patient presented with worsening palpitations and insomnia after 3 weeks of liraglutide use.
  8. 08HumanCase report or seriesSafety outcome

    In a 34-year-old woman after 3 weeks of liraglutide use for weight loss, examination found no tremor; this was a descriptive case observation.

    In plain wordsIn one woman after liraglutide use, examination found no tremor; this was a case observation.

    Peptide
    Liraglutide
    Outcome
    Not applicableNo tremor on examination
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Examination revealed sinus tachycardia with no goitre or tremors.
    2 context sentences
    Summary · context
    This report describes the case of a 34-year-old woman with new-onset hyperthyroidism following liraglutide use for weight loss.
    Summary · context
    The patient presented with worsening palpitations and insomnia after 3 weeks of liraglutide use.
  9. 09HumanCase report or seriesSafety outcome

    In a 34-year-old woman after 3 weeks of liraglutide use for weight loss, thyrotropin receptor antibody was negative, ruling out Graves disease; this was a descriptive case observation.

    In plain wordsIn one woman after liraglutide use, thyrotropin receptor antibody was negative, ruling out Graves disease; this was a case observation.

    Peptide
    Liraglutide
    Outcome
    Not applicableNegative thyrotropin receptor antibody
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Thyrotropin receptor antibody was negative, ruling out Graves' disease.
    2 context sentences
    Summary · context
    This report describes the case of a 34-year-old woman with new-onset hyperthyroidism following liraglutide use for weight loss.
    Summary · context
    The patient presented with worsening palpitations and insomnia after 3 weeks of liraglutide use.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 10HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome

    In a 34-year-old woman, thyroid function normalized within weeks after liraglutide cessation and carbimazole/propranolol treatment; the sequence did not isolate drug withdrawal.

    In plain wordsIn one woman, thyroid function normalized after stopping liraglutide and receiving carbimazole and propranolol; withdrawal alone was not isolated.

    Peptide
    Liraglutide
    Outcome
    Not applicableThyroid-function normalization after discontinuation and rescue regimen
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones

    Source sentences

    Summary
    Liraglutide was discontinued, and the patient was treated with carbimazole and propranolol, resulting in symptom resolution and normalisation of thyroid function within weeks.
    2 context sentences
    Summary · context
    This report describes the case of a 34-year-old woman with new-onset hyperthyroidism following liraglutide use for weight loss.
    Summary · context
    The patient presented with worsening palpitations and insomnia after 3 weeks of liraglutide use.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 11HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome

    In a 34-year-old woman, symptoms resolved within weeks after liraglutide cessation plus carbimazole and propranolol; no isolated withdrawal effect was established.

    In plain wordsIn one woman, symptoms resolved after stopping liraglutide and receiving carbimazole and propranolol; withdrawal alone was not isolated.

    Peptide
    Liraglutide
    Outcome
    Not applicableSymptom resolution after discontinuation and rescue regimen
    Study

    n = 1

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Liraglutide was discontinued, and the patient was treated with carbimazole and propranolol, resulting in symptom resolution and normalisation of thyroid function within weeks.
    2 context sentences
    Summary · context
    This report describes the case of a 34-year-old woman with new-onset hyperthyroidism following liraglutide use for weight loss.
    Summary · context
    The patient presented with worsening palpitations and insomnia after 3 weeks of liraglutide use.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.